Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Surgeons who specialize in Prostate Cancer

Mitchell Bamberger, MD, Attending Physician
Tri-County Urology
Analysis of: Finnish Multicenter Study Comparing Intermittent To Continuous Androgen Deprivation For Advanced Prostate Cancer (www.medicalnewstoday.com)
prostate cancer, hormonal therapy, intermittent treatemtent
Mitchell Bamberger, MD, Attending Physician
Tri-County Urology
Analysis of: Approval From The Swedish Medical Products Agency To Start A Clinical Trial Using A Xenogenic PSA DNA Vaccine (www.medicalnewstoday.com)
prostate cancer, vaccine, dna
Michael Wolff, MD, Urologist
Michael Wolff, MD, Urologist
Alamance Regional Medical Center, Inc
Analysis of: Watson Announces Positive Data for Its Investigational Oxybutynin Topical Gel for the Treatment of Overactive Bladder at SUNA's Annual Conference (www.pipelinereview.com)
Ditropan XL and generic ditropan have significant side effects and oxytrol patches can cause skin irritation. These problems may be avoided with oxybutinin gel.
Michael Wolff, MD, Urologist
Michael Wolff, MD, Urologist
Alamance Regional Medical Center, Inc
Analysis of: Mixed Outcomes in Laparoscopy for Prostates (www.nytimes.com)
Robotic prostatectomy has been successfully marketed by Intuit without much clinical data backing up potential benefits.
Mitchell Bamberger, MD, Attending Physician
Tri-County Urology
Analysis of: Mixed Outcomes in Laparoscopy for Prostates (www.nytimes.com)
The data gives a mixed review regarding the robotic assisted radical prostatectomy for prostate cancer.  There is a clear advantage in regards to a significantly decreased risk of bleeding, post operative pain, and earlier return to normal activities.  However, the data does not show a clinical...
Mitchell Bamberger, MD, Attending Physician
Tri-County Urology
Analysis of: Cell Genesys Announces Encouraging Results from Phase 1/2 Trial of GVAX Immunotherapy for Prostate Cancer in Recurrent Disease (www.pipelinereview.com)
Novel therapy for advance recurrent prostate cancer that does not rely upon traditional standard hormone therapy. This has the potential for men to continue to be sexually active while receiving treatment for advanced disease.  It also opens the door to other therapeutic interventions.
Michael Wolff, MD, Urologist
Michael Wolff, MD, Urologist
Alamance Regional Medical Center, Inc
Analysis of: Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia (pharmalive.com)
Silodosin NDA has been accepted for filing by the FDA. BPH is a very common conditin in men over the age of 50 years and this segment of the population is rapidly growing. However, many treatments are already available.
Michael Wolff, MD, Urologist
Michael Wolff, MD, Urologist
Alamance Regional Medical Center, Inc
Analysis of: AMAG Pharmaceuticals, Inc. Submits New Drug Application to FDA for Ferumoxytol in Chronic Kidney Disease Patients (www.pipelinereview.com)
The recent approval of once daily Cialis at low dosages further adds to the concept that spontaneity is better with respect to sexual activity and helps  Eli Lilly further distinguish its product from Viagra and Levitra.
Michael Wolff, MD, Urologist
Michael Wolff, MD, Urologist
Alamance Regional Medical Center, Inc
Analysis of: Desmopressin Acetate (marketed as DDAVP Nasal Spray, DDAVP Rhinal Tube, DDAVP, DDVP, Minirin, and Stimate Nasal Spray) (www.fda.gov)
Desmopressin (DDAVP) has been available for many years as a nasal spray and more recently as a tablet. This warning should already be well known to most physicians.
Mitchell Bamberger, MD, Attending Physician
Tri-County Urology
Analysis of: Desmopressin Acetate (marketed as DDAVP Nasal Spray, DDAVP Rhinal Tube, DDAVP, DDVP, Minirin, and Stimate Nasal Spray) (www.fda.gov)
The FDA has made the nasal spray formulation of DDAVP be withdrawn due to potential significant side effects of life threatening hyponatremia (low blood sodium) as well as potential seizures. I an unable to identify the data from this announcement as to why this occured. DDAVP nasal spray has been used...

Page : 1 2 3 Next1 to 10 of 30

Analytics


Generated at 2009-01-09T13:00:20.343